Theranica develops advanced, clinically proven, safe and affordable digital therapeutics, addressing some of the world’s most prevalent neurological pain diseases. Self-described as offering prescription digital therapeutics for pain management.

Theranica

Theranica | 11,046 followers on LinkedIn. A new era in migraine therapy | Theranica is a neuromodulation therapeutics company dedicated to creating effective, safe, affordable, and low-side-effect therapies for idiopathic pain conditions. Our initial focus is on migraine, one of the most common neurologic disorders affecting over 1 billion people, with a high prevalence and morbidity, especially among adolescents and females. 
 
The company’s award-winning flagship Nerivio® REN wearable is changing the game for migraine sufferers, especially the 100 million adolescents facing this complex and non-curable disease.

Vice President of R&D and Co Founder,Theranica Bio Electronics

Slava Barabash

Yoni Cheifetz

Co-Founder, Chief Operating Officer Marketing | Business Development | Operations

Ronen J.

CEO and co-founder of Theranica, where we harness neuroscience and technology to improve the quality of life of millions of kids and adults living…

Alon Ironi

Migraine affects 100 million children worldwide. [1]* That’s a big patient population, but let’s unpack what the bigger implications of this are. > These young patients are at a higher risk of their disease worsening and becoming chronic into adulthood. [2] > This matters because adolescence is a key imprinting stage of life, and uncontrolled migraine disease can negatively impact life trajectory and can potentially bring on other disabilities. [2] > Early and effective intervention with both preventive and acute treatments is essential to break this cycle. [3] >However, there are limited treatment options available that can be poorly tolerated, disruptive, and require adult management, which can deter timely intervention and adherence. [4] Fortunately, there is a solution to consider. The Nerivio® REN wearable offers a different approach, providing a safe, effective, and well-tolerated treatment option for adolescents. Jen Odweyer, whose daughter has struggled with migraine for years, shared her perspective of how the REN wearable made a significant difference: "It’s been absolutely life-changing for her. She was on medication since she was 13 and has had migraine for 10 years now… She has tried every migraine medication under the sun, but the side effects were worse than the migraine. We cannot thank Nerivio enough." It’s time to rethink first-line migraine interventions. By integrating appropriate non-drug, non-disruptive treatments, like the REN wearable, into adolescent care plans from the time of diagnosis, healthcare providers can help ensure early and effective intervention to mitigate long-term disability. Listening to the experiences of parents and caregivers is crucial for finding the right care for adolescents with migraine. Discover how Theranica's Nerivio REN wearable can make a difference in their lives. Follow Theranica to learn more. —----------------------------------------- 1. Kabbouche et al, “Management of migraine in adolescents”, 2008. 2. Charles et al,“Favorable outcome of early treatment of new onset child and adolescent migraine-implications for disease modification”, 2009. 3. Al-Futaisi, Amna, “Pediatric Migraines: A Comprehensive Review and Perspectives on Diagnosis and Treatment”, 2023. 4. Evers et al, “Clinical features, pathophysiology, and treatment of medication-overuse headache”, 2010. *Nerivio® is a neuromodulation device indicated for the acute and/or preventive treatment of migraine with or without aura in patients 12 years of age and up. Nerivio can be obtained with a medical prescription. As with any therapy, there may be side effects and contraindications. Not all patients respond to the therapy in the same way, meaning that treatment results can vary individually. Consult with your healthcare provider to see if Nerivio is right for you. More information about Nerivio can be found here: Nerivio.com .

Did you know that headaches rank among the top five health problems in children and is the third most common reason for ER visits?[1] Children with migraine disease also miss twice as many school days as their peers without the condition, disrupting not just their education, but also their social lives and long-term futures.[2] These statistics highlight a critical need for better migraine treatment and demonstrate that migraine is far more complex than an ordinary headache. The Nerivio® REN wearable is a unique, dual-use treatment for migraine disease. Self-administered and controlled via a smartphone app, the REN wearable enables adolescents to independently initiate their treatments without the need for adult supervision, empowering them to actively manage their health, and fostering a sense of autonomy and control. Follow Theranica to learn more about the Nerivio REN wearable. —-------------------------------------------------------- 1. Tilleman et al, “Identifying and Treating Migraines in Children”, 2014. 2. Koch et al, “Pediatric migraine: Diagnostic criteria and treatment”, 2018. *Nerivio® is a neuromodulation device indicated for the acute and/or preventive treatment of migraine with or without aura in patients 12 years of age and up. Nerivio can be obtained with a medical prescription. As with any therapy, there may be side effects and contraindications. Not all patients respond to the therapy in the same way, meaning that treatment results can vary individually. Consult with your healthcare provider to see if Nerivio is right for you. More information about Nerivio can be found here: Nerivio.com .

Visit Theranica at Booth #702 at the 53rd Annual Annual Child Neurology Society Meeting, November 11 - 14, to explore the latest advancements in migraine treatment. Learn more here: https://lnkd.in/eXUzDCP8

There is a critical window of opportunity to significantly address migraine in children and adolescents before it progresses into a more chronic condition.[1] Early and targeted treatment is crucial in potentially modifying the disease and preventing long-term complications.[2] Yet, many prescription medications were not initially developed for migraine and often fall short for this age group because they are poorly tolerated and disruptive. Inadequate treatment during adolescence can lead to chronification of migraine into adulthood, making timely and effective intervention essential. Children and adolescents who receive appropriate therapy early in their migraine journey often respond better and experience less disability.[1]* The Nerivio® REN wearable is designed for the unique needs of young patients who experience the pain and disability of migraine disease. With its proven safety profile and ease of use, it could be considered a first-line option for adolescent migraine treatment. Learn more here: Nerivio.com —--------------------------------------------- 1. Charles et al, “Favorable outcome of early treatment of new-onset child and adolescent migraine-implications for disease modification”, 2009. 2. Pescador Ruschel et al, “Migraine Headache”, 2024. *Nerivio® is a neuromodulation device indicated for the acute and/or preventive treatment of migraine with or without aura in patients 12 years of age and up. Nerivio can be obtained with a medical prescription. As with any therapy, there may be side effects and contraindications. Not all patients respond to the therapy in the same way, meaning that treatment results can vary individually. Consult with your healthcare provider to see if Nerivio is right for you. More information about Nerivio can be found here: Nerivio.com .

Exciting News: Medicaid Coverage Expanded for the Nerivio® REN wearable in Four More States! Following the lead of Colorado and Washington D.C., we’re thrilled to announce that Medicaid coverage for the REN wearable has expanded to Arizona, New Jersey, Ohio, and Virginia—bringing an additional seven million people access to this innovative, non-drug migraine treatment. This recent news marks a new era for migraine care in healthcare, allowing access to innovative migraine treatment. This is particularly important for populations with limited treatment options, such as adolescents, who are at risk of migraine chronification if not treated properly. The REN wearable, FDA-cleared for both acute and preventive migraine treatment, provides a safe and effective alternative to traditional drug therapies. With the risk of side effects from prescription medications, this coverage is critical to help reduce the financial burden and improve access to care for patients. We remain dedicated to expanding access to the REN wearable so that more patients living with migraine can benefit from safe intervention and proven long-term outcomes. We urge remaining states to follow suit and help provide affordable access to this game-changing, non-drug migraine treatment. For more information, visit www.nerivio.com .

The Need for Comprehensive Migraine Treatment Coverage Migraine is more than just a headache. It's a condition that significantly impacts the quality of life of over 37 million people in the United States.[1] With traditional migraine medications having limitations and potential side effects, it's crucial that health plans recognize the importance of non-drug, non-disruptive treatments like the Nerivio® REN wearable. >Rising Prevalence: Migraine continues to affect a growing number of individuals [2] >Medication Limitations: Conventional migraine medications can be unsuitable for many, particularly younger patients or those with complex health conditions, due to systemic side effects. [3] >Quality of Life: The impact of migraine on daily life is profound, often comparable to arthritis or cancer in terms of quality of life disruption. [4] Non-drug treatments may offer relief without interfering with daily activities or requiring complex management. >Prevention Potential: Integrating non-drug treatments like the REN wearable into treatment plans in adolescents can be pivotal for early intervention, potentially reducing the long-term burden of migraine. [5] For a modeled US commercial health plan with one million members, covering Nerivio could lead to about $7,000 in annual cost savings per member. [6] At Theranica, we’re continuing to push for comprehensive coverage to improve patient outcomes and provide those with migraine the treatment they need and deserve. Learn more here: Nerivio.com —------------------------------------------- 1. American Migraine Foundation, “Facts about Migraine”, 2019. 2. Amiri et al, “Migraine: A Review on Its History, Global Epidemiology, Risk Factors, and Comorbidities”, 2021. 3. Lew et al, “Migraine Medications”, 2023. 4. Powers et al, “Quality of Life in Childhood Migraines: Clinical Impact and Comparison to Other Chronic Illnesses”, 2008. 5. Monteith et al, “Remote electrical neuromodulation (REN) wearable device for adolescents with migraine: a real-world study of high-frequency abortive treatment suggests preventive effects”, 2023. 6. Cowan et al, “Clinical benefits and economic cost-savings of remote electrical neuromodulation (REN) for migraine prevention”, 2023.

Migraine disease significantly impacts the lives of adolescents, disrupting both daily activities and their futures. Migraine can lead to school absenteeism, an inability to participate in social activities, and long-term socioeconomic consequences. In fact, the negative impact on the quality of life for these children* is comparable to that of those living with arthritis and cancer.[1] A 2022 survey from “The Migraine Trust” [2] reveals the harsh realities faced by adolescents living with migraine disease: >Younger children often struggle to explain their migraine or aren't always believed when they do. >Older children are often unprepared for managing migraine as adults, facing new triggers and barriers in different environments, such as the workplace or independently navigating healthcare. >There is a strong desire among young people and their families to connect with others who understand what they’re going through. Many young people with migraine report feeling isolated, alone, and different. These findings underscore the need for a treatment designed for adolescents and their specific needs. The Nerivio® REN wearable allows patients ages 12 and up to self-administer their treatments in a non-disruptive way that fits seamlessly into their daily routines. This matters because early treatment and prevention are key to minimizing future disability and preventing the chronification of migraine into adulthood. Read the full survey here: https://lnkd.in/gUEMs_PD —-------------------------------- 1. Powers et al, “Quality of Life in Childhood Migraines: Clinical Impact and Comparison to Other Chronic Illnesses”, 2008. 2. The Migraine Trust, “Dismissed for too long The impact of migraine on children & young people”, 2022. *Nerivio® is a neuromodulation device indicated for the acute and/or preventive treatment of migraine with or without aura in patients 12 years of age and up. Nerivio can be obtained with a medical prescription. As with any therapy, there may be side effects and contraindications. Not all patients respond to the therapy in the same way, meaning that treatment results can vary individually. Consult with your healthcare provider to see if Nerivio is right for you. More information about Nerivio can be found here: Nerivio.com .

Veterans face unique health challenges, and migraine disease is no exception. In fact, the Veterans Administration (VA) reported that 36% of veterans who have completed a one-year tour in Iraq were diagnosed with, or showed signs of, migraine symptoms, a 3x greater frequency of migraine than the general population. [1] Veterans may also endure the following: >More than 1 in 3 returning military troops who have sustained a deployment-related concussion experience headaches that meet the criteria for posttraumatic headache, with migraine being the predominant headache type.[2] >Compared with headaches not directly attributable to head trauma, posttraumatic headaches are associated with a higher frequency of attacks and an increased prevalence of chronic conditions.[2] The Nerivio® REN wearable is a non-drug, non-disruptive treatment option that delivers effective relief from migraine symptoms without the side effects of traditional medications. This treatment empowers veterans to regain control over their health and well-being, offering a path to relief and recovery. Best of all, the Nerivio REN wearable is also covered under VA benefits, making it an accessible option for those who have served. To learn more about how the REN wearable can help veterans, visit https://lnkd.in/eJYX2SwB —-------------------------------------------- 1. V.A. News, “Veterans who deployed are more likely to develop migraines or headache disorders”, 2017. 2. Theeler et al, “Headaches after concussion in US soldiers returning from Iraq or Afghanistan”, 2010.

Metric
Company Name	Theranica
Symbol
MSH ID	COM:THERANICA
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Medical Devices
Country	IL
Stage
Employee Count
Website	theranica.com
LinkedIn	theranica-bio-electronics
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

THER

COM:THERANICA

Theranica

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue